The invention provides methods and materials for culturing mammalian cells and harvesting recombinant protein.

A method for asymmetrically preparing L-phosphinothricin by oxidation-reduction reaction through biological multienzyme coupling, where D,L-phosphinothricin as a raw material is catalyzed by an enzyme catalysis system to obtain L-phosphinothricin, wherein the enzyme catalysis system comprises a D-amino acid oxidase mutant for catalyzing D-phosphinothricin in D,L-phosphinothricin into 2-carbonyl-4-[hydroxy(methyl)phosphono]butyric acid and a transaminase for catalytic reduction of the 2-carbonyl-4-[hydroxy(methyl) phosphono]butyric acid into L-phosphinothricin; the D-amino acid oxidase mutant is obtained by mutation of D-amino acid oxidase in wild strain Rhodotorula taiwanensis at one of the following four sites: (1) M213S; (2) M213S-N54V-F58E; (3) M213S-N54V-F58E-D207A; (4) M213S-N54V-F58E-D207A-S60T. According to the present invention, the D-amino acid oxidase mutant provides better catalytic efficiency, and when racemic D,L-phosphinothricin is used as a substrate for catalytic reaction, the conversion rate is much higher than that of the wild type enzyme, and the PPO yield is also greatly improved.

The present invention relates to compositions and methods for mass production of pluripotent stem cells derived from non-human-animal, particularly in a form of aggregates suitable for a variety of uses, particularly to mass production of aggregates of bovine-derived pluripotent stem cells for use in cell grown meat cultures and in production of cell based meat products.

Described herein are systems and methods relating to three-dimensional (3D) cell manufacturing utilizing a 3D growth media. According to aspects of the present disclosure, pluralities of cells and ECM components can be printed into a bioreactor as a sheet. Sheets can be retrieved, digested, split, and re-printed, thereby expanding the number of cells in an efficient manner that conserves space in a tissue culture incubator, conserves bioreactor consumables, and consumes nutrients required for cell maintenance and growth.

Provided are a medium composition for culturing animal cells for producing a recombinant extracellular matrix protein, a method of producing the recombinant extracellular matrix protein with high purity, and a method of assaying a monomer of the recombinant extracellular matrix protein.

A process for producing blood coagulation Factor VII in large scale in 3 human cell lines (HepG2, Sk-Hep, and HKB-11) and to select the best recombinant protein producer is described. The murine line BHK-21 was used as control. The data allowed for the assertion that the system used to modify cell lines was efficient, so that all the cells were satisfactorily modified, and produced the protein of interest in a stable form. In addition, when comparing the murine line BHK-21 with the human cells (HepG2, Sk-Hep-1 and HKB-11), the latter proved to be able to produce rFVII more efficiently, which allows us to conclude that human cell lines are a great alternative to produce recombinant blood coagulation factors in large scale.

The present invention refers to a method to convert H.sub.2 and CO.sub.2 into methane by methanogenic microorganisms in a bioreactor in a continuous production process for methane enriched gas compositions, while culturing the methanogenic microorganisms under cell retention conditions and continuously removing metabolic water in the cell culture medium.

The present invention relates to a method for modifying the glycosylation profile of a recombinant glycoprotein produced in cell culture comprising culturing eukaryotic cells expressing the recombinant glycoprotein in a cell culture medium, wherein the cell culture medium is supplemented with fucose, manganese, and taurine, wherein the glycosylation profile of the produced recombinant glycoprotein is modified to better resemble the glycosylation profile of a reference glycoprotein than when cultured without said supplementation.

Provided herein are methods of producing adeno-associated virus (AAV) comprising culturing AAV producer cell lines in a seed culture followed by an AAV production culture.

The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.